Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light a version in subjects in need thereof, especially migraine sufferers

Patent metadata

Field	Value
Publication number	US-11325967-B2
Application number	US-201916388184-A
Country	US
Kind code	B2
Filing date	Apr 18, 2019
Priority date	May 20, 2011
Publication date	May 10, 2022
Grant date	May 10, 2022

Abstract

The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine. Specifically, this invention relates to assays and therapies using the antibodies described herein to inhibit or prevent photophobia, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them.

First claim

What is claimed is:

1. A method of assessing the potential efficacy of a candidate anti-CGRP antibody or antibody fragment in inhibiting Calcitonin Gene Related Peptide (CGRP)-associated photophobia or light aversion or precluding the onset of CGRP-associated photophobia or photoaversion associated with a migrainous condition or cluster headache condition in a subject comprising determining whether the antibody or antibody fragment inhibits light aversive behavior in a first Nestin/hRAMP1 rodent administered CGRP and the candidate antibody or antibody fragment compared to the light aversive behavior in a second Nestin/hRAMP1 rodent administered CGRP in the absence of the candidate anti-CGRP antibody or antibody fragment, wherein said candidate anti-GRP antibody or antibody fragment is a variant of an anti-CGRP antibody comprising a variable light (VL) polypeptide comprising the VL CDRs of SEQ ID NO: 55, 56 and 57 and a variable heavy (VH) polypeptide comprising the VH CDR polypeptides of SEQ ID NO: 58, 59 and 60 wherein said variant comprises said CDR polypeptides with the exception that one of the CDR residues in one of the CDRs of said VH or in one of the CDRs of said VL polypeptide has been substituted with another amino acid residue.

2. The method of claim 1 , wherein said anti-CGRP antibody or antibody fragment is human, humanized, or chimeric.

3. The method of claim 2 , wherein said anti-CGRP antibody or antibody fragment is humanized.

4. The method of claim 3 , wherein the humanized anti-CGRP antibody or antibody fragment comprises human constant regions selected from the group consisting of IgG1, IgG2, IgG3 and IgG4 constant regions.

5. The method of claim 1 , wherein said anti-CGRP antibody fragment is an scFv, camelbody, nanobody, IgNAR, Fab, Fab′, or F(ab) 2 fragment.

6. The method of claim 1 , wherein said anti-CGRP antibody or antibody fragment is non-glycosylated.

7. The method of claim 1 , wherein said anti-CGRP antibody or antibody fragment comprises a variable light (VL) polypeptide having a sequence possessing at least 90% sequence identity SEQ ID NO: 51 and further comprises a variable heavy (VH) polypeptide having a sequence possessing at least 90% sequence identity to SEQ ID NO: 53.

8. The method of claim 1 , wherein said anti-CGRP antibody or antibody fragment binds to CGRP with an off-rate (K off ) of less than or equal to 10 −4 S −1 , 5×10 −5 S −1 , 10 −5 S −1 , 5×10 −6 S −1 , 10 −6 S −1 , 5×10 −7 S −1 , or 10 −7 S 1 .

9. The method of claim 1 , wherein said anti-CGRP antibody has an Fc region that contains a mutation that alters or eliminates glycosylation or another Fc effector function.

10. The method of claim 1 , wherein said anti-CGRP antibody or antibody fragment comprises a variable light (VL) polypeptide having a sequence possessing at least 95% sequence identity SEQ ID NO: 51 and further comprises a variable heavy (VH) polypeptide having a sequence possessing at least 95% sequence identity to SEQ ID NO: 53.

Assignees

• H Lundbeck As
• The Univ Of Iowa Research Foundation

Inventors

• Russo Andrew F
• Kaiser Eric A
• Recober Ana
• Kuburas Adisa
• Raddant Ann C
• Kovacevich Brian R
• Latham John
• Smith Jeffrey T L
• Garcia-Martinez Leon F

Classifications

• C07K16/18 Primary

  against material from animals or humans · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P25/22

  Anxiolytics · CPC title

• A61P27/12

  for cataracts · CPC title